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Multiple sclerosis (MS) is the most frequent disabling chronic inflammatory 
demyelinating disease in young adults. Over the past decade, substantial progress 
has been made with respect to the treatment of MS leading to several new effective 
drugs entering the post-marketing setting. In addition to the positive effects of early 
and efficient MS therapy in terms of clinical and imaging outcome measures, some 
therapeutics may lead to undesirable adverse effects including opportunistic 
infections. One of the most frequent opportunistic infections occurring during MS 
pharmacovigilance is progressive multifocal leukoencephalopathy (PML), a lytic 
infection of grey and white matter cells in the brain caused by JC virus. In particular, 
this has been demonstrated in MS patients treated with natalizumab, a humanized 
monoclonal antibody against the adhesion molecule α4-integrin. In addition to 
clinical vigilance and cerebrospinal fluid testing, magnetic resonance imaging (MRI) 
is the most important and sensitive method for the detection of PML. This thesis 
investigates the value of brain MRI in the monitoring and detection of PML in the 
pharmacovigilance setting of natalizumab treated MS patients by exploring PML 
imaging patterns, the value of MRI identifying PML in an early stage and by 
developing strategies for screening in patients classified as higher risk of developing 
PML.    
The role of MRI in 
pharmacovigilance of natalizumab-treated MS patients: 
a “known unknown”?
Mike P Wattjes




S patients: a known unknown?            M
ike P W
attjes
Wattjes Doktorarbeit Umschlag.indd   1 16.04.19   15:51
Multiple sclerosis (MS) is the most frequent disabling chronic inflammatory 
demyelinating disease in young adults. Over the past decade, substantial progress 
has been made with respect to the treatment of MS leading to several new effective 
drugs entering the post-marketing setting. In addition to the positive effects of early 
and efficient MS therapy in terms of clinical and imaging outcome measures, some 
therapeutics may lead to undesirable adverse effects including opportunistic 
infections. One of the most frequent opportunistic infections occurring during MS 
pharmacovigilance is progressive multifocal leukoencephalopathy (PML), a lytic 
infection of grey and white matter cells in the brain caused by JC virus. In particular, 
this has been demonstrated in MS patients treated with natalizumab, a humanized 
monoclonal antibody against the adhesion molecule α4-integrin. In addition to 
clinical vigilance and cerebrospinal fluid testing, magnetic resonance imaging (MRI) 
is the most important and sensitive method for the detection of PML. This thesis 
investigates the value of brain MRI in the monitoring and detection of PML in the 
pharmacovigilance setting of natalizumab treated MS patients by exploring PML 
imaging patterns, the value of MRI identifying PML in an early stage and by 
developing strategies for screening in patients classified as higher risk of developing 
PML.    
The role of MRI in 
pharmacovigilance of natalizumab-treated MS patients: 
a “known unknown”?
Mike P Wattjes




S patients: a known unknown?            M
ike P W
attjes
Wattjes Doktorarbeit Umschlag.indd   1 16.04.19   15:51
